期刊文献+

非侵入性指标预测慢性乙型肝炎严重程度价值分析 被引量:6

Value of non-invasive parameters in predicting severity of chronic hepatitis B
下载PDF
导出
摘要 目的 探讨应用非侵入性指标预测慢性乙型肝炎患者肝组织学改变程度的价值.方法 纳入2013年1-12月山东省青岛市中心医院78例初发慢性乙型肝炎患者,记录其基本临床资料及常规实验室检查结果,计算天冬氨酸转氨酶(AST)/丙氨酸转氨酶(ALT)比值(AAR)、AAR/血小板比值(AARPRI)、AST/血小板比值(APRI)、年龄/血小板比值(API)数值.对所有患者进行经皮肝活检,按肝组织炎症活动度(NIA)分为轻度肝炎和中重度肝炎;按肝纤维化程度分为轻度肝纤维化和中重度肝纤维化.运用多种统计学方法评估AAR、AARPRI、APRI、API、年龄等指标与肝NIA和纤维化程度的关系.结果 轻度肝炎患者(44例)AAR、AARPRI、APRI、API分别为(0.78±0.37)、(0.58±0.28)、(0.83 ±0.47)、(2.59±1.85),中重度肝炎患者(34例)分别为(0.73±0.25)、(0.61±0.30)、(3.15±1.93)、(3.92±2.31);轻度肝纤维化患者(43例)AAR、AARPRI、APRI、API分别为(0.76±0.33)、(0.57±0.27)、(0.85 ±0.50)、(2.70±1.87),中重度肝纤维化患者(35例)分别为(0.75±0.31)、(0.62±0.31)、(3.18±1.92)、(3.80±2.36).中重度肝炎患者APRI、API明显高于轻度肝炎患者,中重度肝纤维化患者APRI、API明显高于轻度肝纤维化患者,差异均有统计学意义(均P <0.05).Spearman秩相关检验表明年龄、AST、ALT、AARPRI、APRI和API与肝组织学NIA分级(r=0.23、0.31、0.22、0.25、0.37、0.36,均P<0.05)和肝纤维化程度显著相关(r=0.31、0.30、0.22、0.24、0.38、0.31,均P<0.05).APRI[比值比(OR)=2.35,P=0.01]和年龄(OR=1.04,P<0.01)是肝NIA分级的独立预测因子.AARPRI(OR=3.80,P=0.07)、年龄(OR=1.04,P=0.02)和ALT(OR=1.01,P<0.01)水平是肝纤维化的独立预测因子.应用受试者工作特征曲线进一步分析却显示上述预测因子都不具备很好的预测价值(曲线下面积<0.70),其中APRI预测效能最高,敏感度和特异度分别为0.65和0.71.结论 仅APRI对肝脏疾病的预测具有较高敏感度和特异度,有可能用于慢性乙型肝炎严重程度的预测. Objective To assess the value of non-invasive parameters in predicting severity of chronic hepatitis B (CHB).Methods Clinical data of 78 patients with untreated CHB from January to December 2013 were retrospectively analyzed.The demographic characteristics and laboratory parameters were recorded.The ratioof aspartate aminotransferase (AST) to alanine aminotransferase (ALT) (AAR),ratio of AAR to platelet count (AARPRI),ratio of AST toplatelet count (APRI),and ratio age to platelet count (API) were calculated.Thepercutaneous liver biopsy was preformed to determine the mild,moderate/severe inflammation,mild hepatic fibrosis and moderate/severe hepatic fibrosis.The correlations of between AAR,AARPRI,APRI,API,age and degree of hepatic inflammation and fibrosis were analyzed.Results AAR,AARPRI,APRI,API were (0.78 ±0.37),(0.58 ±0.28),(0.83 ±0.47),(2.59 ± 1.85) in mild hepatitis patients;they were (0.73 ± 0.25),(0.61 ± 0.30),(3.15 ± 1.93),(3.92 ± 2.31) in moderate/severe hepatitis patients,respectively.AAR,AARPRI,APRI,API were (0.76 ± 0.33),(0.57 ± 0.27),(0.85 ± 0.50),(2.70 ± 1.87) in patients with mild hepatic fibrosis;they were(0.75 ± 0.31),(0.62 ± 0.31),(3.18 ± 1.92),(3.80 ± 2.36) in patients with severe hepatic fibrosis.APRI and API were significantly higher in moderate/severe hepatitis patients than those in mild hepatitis patients.The age,AST,ALT,AARPRI,APRI and API were significantly correlated with degree of hepatic inflammation (r =0.23,0.31,0.22,0.25,0.37,0.36) and fibrosis (r =0.31,0.30,0.22,0.24,0.38,0.31) (P 〈 0.05).The independent risk factors of degree of hepatic inflammation included APRI (odds ratio =2.35,P =0.01) and age (odds ratio =1.04,P 〈 0.01);the independent predictors of hepatic fibrosis included AARPRI (odds ratio =3.80,P =0.07),age (odds ratio =1.04,P =0.02),and ALT (odds ratio =1.01,P 〈 0.01).Conclusion The APRI can help to predict the severity of liver disease in patients with CHB.
出处 《中国医药》 2015年第8期1149-1153,共5页 China Medicine
关键词 慢性乙型肝炎 肝纤维化 肝组织学坏死和炎症 Chronic hepatitis B Liver fibrosis Liver histology necrosis and inflammation
  • 相关文献

参考文献8

二级参考文献58

共引文献57

同被引文献45

  • 1Ott JJ,Stevens GA,Groeger J,et al. Global epidemiology of hepatitis B virus infection: New estimates of age-spe- cific HBsAg seroprevalence and endemicity[J]. Vaccine, 2012,30(12) :2212-2219.
  • 2European Association forthe Study of the Liver,Asociacion Latinoamericana parael Estudiodel Higado.EASL-ALEH clinical practice guidelines:Non-invasive tests for evalua- tion of liver disease severity and prognosis[J]. Journal of Hhepatology, 2015,63 ( 1 ) : 237-264.
  • 3Chen YP,Peng Jie,Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B[J]. Hepa- tology International, 2013,7 (2) : 356-368.
  • 4M Schfiniger-HEKELE, C Mti Ller. The combined eleva- tion of tumor markers CA 19-9 and CA 125 in liver dis- ease patients is highly specific for severe liver fibrosis[J]. Digestive Diseases and Sciences, 2006,51 (2) : 338-345.
  • 5Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: Comparison of the APRI and FIB-4 index[J]. Clin Chim Acta, 2008,397 (1-2) : 51-54.
  • 6Tong Yuling, Song Zhenya, Zhu Weihua. Study of an ele- vated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China[J]. Clinical Chemistry and Laboratory Medicine : CCLM/FESCC, 2013,51 (7) : 1459-1466.
  • 7Gaetano Bertino, Annalisa Maria Ardiri, Giuseppe Ste- fano Calvagno,et al. Carbohydrate 19.9 antigen serum levels in liver disease[J]. BioMed Research International, 2013, (10) : 531640.
  • 8刘卫平,许德军,赵连荣,陆忠华,王玉华,郎振为,王贵强.慢性乙型肝炎肝纤维化无创检测模型建立及应用价值验证[J].中华内科杂志,2008,47(4):308-312. 被引量:18
  • 9张占卿,曹婕,陆伟,史连国.ROC曲线法评价简易无创模型预测乙型肝炎相关肝硬化[J].胃肠病学和肝病学杂志,2009,18(1):41-44. 被引量:18
  • 10叶希韵,徐敏华,李晓峰,王耀发.山楂叶总黄酮降血脂防治鹌鹑脂肪肝形成的实验研究(英文)[J].复旦学报(医学版),2009,36(2):142-148. 被引量:19

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部